surmount-1 tirzepatide trial obesity without diabetes 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers SURMOUNT-3 study design This is

We need to develop a deeper understanding of our own health

It also helps you identify patterns, such as side effects being worse with certain injection sites or times of day

Assuming a 50 percent price erosion post-generic entry and 50 percent market share capture by generics, the addressable opportunity could be around $500 million

Kidney Function: Semaglutide can cause dehydration, which may lead to kidney problems, especially in patients with pre-existing kidney conditions

The right choice depends on your medical complexity, insurance status, and preference for digital versus in-person healthcare

Is treating metastasis tougher than other cancer work